Supportive care and management of complications in anemia

Article written and reviewed by Dr Luca Moretti

Supportive care is a fundamental pillar in the management of anemia, especially when specific therapies are ineffective, unavailable or cannot be implemented immediately. This approach, which complements etiologic and transfusion strategies, aims to ensure the best possible quality of life, prevent or treat complications and stabilize the clinical condition. In modern clinical practice, care of a patient with anemia requires careful assessment of the general condition, individualized treatment and interdisciplinary collaboration involving, in addition to the hematologist, professionals such as the cardiologist, internist, nutritionist, nephrologist and rehabilitation specialist.

Management of anemia-related complications is based on careful surveillance of the main target organs and prompt, specific interventions tailored to each clinical situation. Both acute and chronic complications can significantly affect prognosis and quality of life, requiring differentiated strategies and consistent follow-up.

Supportive care: general principles and clinical tools

In the management of anemia of any cause, clinical support begins with assessment of symptom severity and the risk of organ decompensation.

Administration of oxygen is indicated in the presence of hypoxemia or specific cardiopulmonary impairment. In anemia with normal arterial oxygen saturation, oxygen does not correct the reduced oxygen content caused by low hemoglobin and does not replace causal or transfusion therapy when indicated.

A central aspect is correction of nutritional deficiencies. Nutritional support is not limited to supplementation with iron, vitamin B12 or folic acid, but includes a comprehensive assessment of nutritional status, with involvement of a nutritionist to define a balanced dietary plan rich in protein and micronutrients and providing calories appropriate to the individual patient's requirements. This support is also crucial for preventing additional metabolic deficiencies, promoting response to treatment and maintaining immune function.

Management of physical activity is another key component. Prolonged immobility can favor thromboembolic complications, loss of muscle mass and increased risk of infection. Conversely, excessive or poorly calibrated physical activity may worsen symptoms related to reduced oxygen delivery and precipitate acute decompensation. A gradual rehabilitation pathway adapted to the patient's general condition should be developed, including mobilization exercises, low-intensity aerobic activity and programs to restore muscle strength.

In immunocompromised or splenectomized patients, prevention of infections plays a strategic role. This is based on a complete and up-to-date vaccination schedule adapted to the specific immunocompromising condition; in splenectomized patients, pneumococcal, meningococcal and Haemophilus influenzae type b vaccination is particularly indicated, in addition to routine vaccines, together with patient education and, in selected cases, prolonged antibiotic prophylaxis. Regular monitoring of body temperature, attention to nonspecific symptoms and prompt management of febrile episodes are key elements of active surveillance.

Prevention of thrombosis follows standard indications based on immobility, hospitalization, surgery, cancer, splenectomy and individual risk. Anemia alone is not an indication for heparin or antiplatelet therapy, which may increase bleeding risk.

Management of the main complications of anemia

Cardiovascular complications

Anemia, particularly when severe or chronic, places a substantial compensatory burden on the cardiovascular system, with increased cardiac output, tachycardia and, over time, ventricular hypertrophy. In vulnerable patients, these adaptations can lead to high-output heart failure, myocardial ischemia and arrhythmias. Cardiac monitoring must be continuous, using investigations such as ECG, echocardiography and, in selected cases, advanced cardiac function testing. Treatment of cardiovascular complications requires prudent correction of anemia and cardiac therapy indicated for the specific hemodynamic condition; diuretics, ACE inhibitors and beta blockers are not automatically appropriate in every case of high-output heart failure. Early recognition of hemodynamic deterioration is essential to intervene before irreversible damage develops.

Neurologic complications

Neurologic symptoms of severe anemia may include confusion or loss of consciousness, but chronic cognitive deficits and stroke have multifactorial etiologies. Management requires correction of the cause of anemia and specific neurologic pathways when indicated; these conditions should not automatically be attributed to anemic hypoxia.

Infectious complications

Infection risk in patients with anemia depends mainly on splenectomy, immunosuppression, neutropenia, malnutrition, prolonged treatment or associated diseases such as kidney failure or malnutrition. Infections may present subtly, with nonspecific symptoms and rapid progression to sepsis. Management is based on vaccination, education for self-monitoring of early warning signs and the adoption of aggressive treatment protocols when infection is documented, including early microbiologic investigations, targeted antibiotic therapy and, in the most severe cases, intensive support.

Metabolic and endocrine complications

Iron overload, frequently observed in patients receiving multiple transfusions or with increased ineffective erythropoiesis, is one of the most concerning metabolic complications because it can involve the heart, liver, pancreas and endocrine system. Iron toxicity may manifest clinically as heart failure, arrhythmias, liver cirrhosis, secondary diabetes mellitus, hypogonadism, hypothyroidism and osteoporosis. Monitoring includes laboratory tests such as ferritin and transferrin saturation, advanced imaging such as MRI to quantify hepatic and cardiac iron, and periodic endocrine testing. Chelation therapy is central to prevention and treatment, using oral or parenteral agents selected and dosed according to the individual benefit-risk balance and tolerability.

Skeletal and osteoarticular complications

Bone impairment in specific chronic anemias may result from iron overload, endocrine disorders, malabsorption, corticosteroids or immobility. Calcium and vitamin D should be administered when insufficiency or a documented requirement is present; bisphosphonates and other antiresorptive agents require a diagnosis of osteoporosis or another specific indication.

Psychosocial complications

Chronic anemia may reduce quality of life and social participation through fatigue, functional limitations and dependence on care. Psychological or rehabilitation support should be offered when clinical needs emerge, without assuming that anxiety, depression or isolation are inevitable consequences of anemia.

Treatment-related complications

Therapies used to manage anemia, such as transfusions, immunosuppressants and chelating agents, can cause specific adverse effects and complications. Allergic reactions, opportunistic infections, organ toxicity and secondary cytopenias are events that depend on the particular treatment; any risk of malignancy must likewise be attributed to the individual therapy and clinical context. These issues require active surveillance, individualized treatment and periodic review of protocols according to patient tolerability. Continuous collaboration between the clinical team and the patient, together with clear communication about expected effects and warning signs, is essential to minimize morbidity and improve treatment adherence.

Bibliography
1. Hoffman R, et al. Hematology: Basic Principles and Practice. 8th ed. Elsevier. 2022.
2. Carson JL, Stanworth SJ, Guyatt G, et al. Red blood cell transfusion: 2023 AABB international guidelines. JAMA. 2023;330(19):1892–1902.
3. Kidney Disease: Improving Global Outcomes Anemia Work Group. KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease. Kidney Int. 2026;109(1S):S1–S99.
4. Taher AT, Musallam KM, Cappellini MD. β-Thalassemias. N Engl J Med. 2021;384(8):727-743.
5. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376(16):1561–1573.
6. Stauder R, Valent P, Theurl I. Anemia at older age: etiologies, clinical implications, and management. Blood. 2018;131(5):505–514.
7. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40-50.
8. Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv96–iv110.
9. Berentsen S, Barcellini W. Autoimmune Hemolytic Anemias. N Engl J Med. 2021;385(15):1407–1419.
10. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832-1843.